- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07881887
A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 전화번호: 1-317-615-4559
- 이메일: LillyTrials@Lilly.com
연구 연락처 백업
- 이름: Physicians interested in becoming principal investigators please contact
- 이메일: clinical_inquiry_hub@lilly.com
연구 장소
-
-
Arkansas
-
Rogers, Arkansas, 미국, 72758
- 아직 모집하지 않음
- Woodland Research Northwest, LLC
-
연락하다:
- 전화번호: 479-927-3000
-
수석 연구원:
- Timothy Cook
-
-
California
-
Anaheim, California, 미국, 92801
- 모병
- CenExel ACT
-
수석 연구원:
- Amina Haggag
-
Los Alamitos, California, 미국, 90720
- 모병
- Collaborative Neuroscience Network - CNS
-
수석 연구원:
- Steven Reynolds
-
Walnut Creek, California, 미국, 94598
- 모병
- Diablo Clinical Research, Inc.
-
수석 연구원:
- Bonnie Kimmel
-
-
Florida
-
Daytona Beach, Florida, 미국, 32117
- 모병
- Fortrea Clinical Research Unit
-
연락하다:
- 전화번호: 866-429-3700
-
수석 연구원:
- Chiamaka Iheme
-
Miami, Florida, 미국, 33417
- 아직 모집하지 않음
- Advanced Pharma CR, LLC
-
수석 연구원:
- Simon Abelson
-
Winter Park, Florida, 미국, 32789
- 모병
- Clinical Site Partners, LLC DBA CSP Orlando
-
수석 연구원:
- ROBERT MEYER
-
-
Georgia
-
Columbus, Georgia, 미국, 31904
- 모병
- Centricity Research
-
수석 연구원:
- Joseph Surber
-
연락하다:
- 전화번호: 706-321-0495
-
Decatur, Georgia, 미국, 30030
- 모병
- CenExel iResearch, LLC
-
수석 연구원:
- Kimball Johnson
-
-
Missouri
-
Springfield, Missouri, 미국, 65802
- 모병
- QPS
-
수석 연구원:
- Leea Reed
-
연락하다:
- 전화번호: 417-893-6161
-
-
New Jersey
-
Marlton, New Jersey, 미국, 08053
- 모병
- CenExel-HRI
-
수석 연구원:
- Kyle Coupe
-
-
Ohio
-
Columbus, Ohio, 미국, 43212
- 모병
- Ohio Clinical Trials
-
수석 연구원:
- Angela Eakin
-
-
Texas
-
Dallas, Texas, 미국, 75247
- 모병
- Fortrea Clinical Research Unit
-
수석 연구원:
- Archie Bowie
-
San Antonio, Texas, 미국, 78217
- 모병
- Worldwide Clinical Trials, Inc.
-
수석 연구원:
- Alan Hand
-
-
-
-
-
Singapore, 싱가포르, 138623
- 아직 모집하지 않음
- Lilly Centre for Clinical Pharmacology
-
연락하다:
- 전화번호: 64139811
-
수석 연구원:
- Jennifer Boon Wee
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participants must be 21 in Singapore.
- Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.
Part A, B, D, and E
-
Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:
- hypertension
- dyslipidemia
- obstructive sleep apnea, or
- prediabetes.
Part C
- Have a BMI ≥25.0 kg/m²
- Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months.
- T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months.
- Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%.
Part D
- To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China.
Part E
- To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.
Exclusion Criteria:
- Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part A: LY4167586
LY4167586 administered subcutaneously (SC) |
administered SC |
|
실험적: Part B LY4167586
LY4167586 administered SC |
administered SC |
|
실험적: Part C LY4167586
LY4167586 administered SC |
administered SC |
|
실험적: Part D LY4167586
LY4167586 administered SC |
administered SC |
|
실험적: Part E LY4167586
LY4167586 administered SC |
administered SC |
|
위약 비교기: Placebo (Part A-E)
Placebo administered SC |
administered SC |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
기간: Baseline through Study Completion (Estimated as Week 89)
|
Baseline through Study Completion (Estimated as Week 89)
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4167586
기간: Baseline up to Week 89
|
Baseline up to Week 89
|
|
PK: Area Under the Concentration Time Curve (AUC) of LY4167586
기간: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Body Weight Observed Value
기간: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Change from Baseline in Body Weight
기간: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Percent Change from Baseline in Body Weight
기간: Baseline up to Week 89
|
Baseline up to Week 89
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .